Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

DL. Kendler, F. Marin, CAF. Zerbini, LA. Russo, SL. Greenspan, V. Zikan, A. Bagur, J. Malouf-Sierra, P. Lakatos, A. Fahrleitner-Pammer, E. Lespessailles, S. Minisola, JJ. Body, P. Geusens, R. Möricke, P. López-Romero,

. 2018 ; 391 (10117) : 230-240. [pub] 20171109

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001098
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy

PubMed 29129436
DOI 10.1016/s0140-6736(17)32137-2
Knihovny.cz E-zdroje

BACKGROUND: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. METHODS: In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1·50. Participants were randomly assigned to receive 20 μg of teriparatide once daily plus oral weekly placebo or 35 mg of oral risedronate once weekly plus daily injections of placebo for 24 months. The primary outcome was new radiographic vertebral fractures. Secondary, gated outcomes included new and worsened radiographic vertebral fractures, clinical fractures (a composite of non-vertebral and symptomatic vertebral), and non-vertebral fractures. This study is registered with ClinicalTrials.gov (NCT01709110) and EudraCT (2012-000123-41). FINDINGS: We enrolled 680 patients in each group. At 24 months, new vertebral fractures occurred in 28 (5·4%) of 680 patients in the teriparatide group and 64 (12·0%) of 680 patients in the risedronate group (risk ratio 0·44, 95% CI 0·29-0·68; p<0·0001). Clinical fractures occurred in 30 (4·8%) of 680 patients in the teriparatide group compared with 61 (9·8%) of 680 in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10). INTERPRETATION: Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate. FUNDING: Lilly.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001098
003      
CZ-PrNML
005      
20200121143842.0
007      
ta
008      
190107s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(17)32137-2 $2 doi
035    __
$a (PubMed)29129436
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kendler, David L $u University of British Columbia, Vancouver, Canada. Electronic address: davidkendler@gmail.com.
245    10
$a Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial / $c DL. Kendler, F. Marin, CAF. Zerbini, LA. Russo, SL. Greenspan, V. Zikan, A. Bagur, J. Malouf-Sierra, P. Lakatos, A. Fahrleitner-Pammer, E. Lespessailles, S. Minisola, JJ. Body, P. Geusens, R. Möricke, P. López-Romero,
520    9_
$a BACKGROUND: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. METHODS: In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1·50. Participants were randomly assigned to receive 20 μg of teriparatide once daily plus oral weekly placebo or 35 mg of oral risedronate once weekly plus daily injections of placebo for 24 months. The primary outcome was new radiographic vertebral fractures. Secondary, gated outcomes included new and worsened radiographic vertebral fractures, clinical fractures (a composite of non-vertebral and symptomatic vertebral), and non-vertebral fractures. This study is registered with ClinicalTrials.gov (NCT01709110) and EudraCT (2012-000123-41). FINDINGS: We enrolled 680 patients in each group. At 24 months, new vertebral fractures occurred in 28 (5·4%) of 680 patients in the teriparatide group and 64 (12·0%) of 680 patients in the risedronate group (risk ratio 0·44, 95% CI 0·29-0·68; p<0·0001). Clinical fractures occurred in 30 (4·8%) of 680 patients in the teriparatide group compared with 61 (9·8%) of 680 in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10). INTERPRETATION: Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate. FUNDING: Lilly.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a Amerika $x epidemiologie $7 D000569
650    _2
$a kostní denzita $x účinky léků $7 D015519
650    _2
$a inhibitory kostní resorpce $x škodlivé účinky $x terapeutické užití $7 D050071
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a Evropa $x epidemiologie $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a lidé středního věku $7 D008875
650    _2
$a postmenopauzální osteoporóza $x komplikace $x farmakoterapie $x epidemiologie $x patofyziologie $7 D015663
650    _2
$a osteoporotické fraktury $x diagnostické zobrazování $x etiologie $x patofyziologie $x prevence a kontrola $7 D058866
650    _2
$a radiografie $7 D011859
650    _2
$a kyselina risedronová $x škodlivé účinky $x terapeutické užití $7 D000068296
650    _2
$a teriparatid $x škodlivé účinky $x terapeutické užití $7 D019379
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Marin, Fernando $u Lilly Research Center, Madrid, Spain.
700    1_
$a Zerbini, Cristiano A F $u Centro Paulista de Investigaçao Clínica, São Paulo, Brazil.
700    1_
$a Russo, Luis A $u CCBR Brasil Centro de Analises e Pesquisas Clinicas, Rio de Janeiro, Brazil.
700    1_
$a Greenspan, Susan L $u Osteoporosis Center, University of Pittsburgh, Pittsburgh, PA, USA.
700    1_
$a Zikan, Vit $u Department of Internal Medicine, General University Hospital, Prague, Czech Republic.
700    1_
$a Bagur, Alicia $u Centro de Osteopatías Comlit, Buenos Aires, Argentina.
700    1_
$a Malouf-Sierra, Jorge $u Hospital Sant Pau, Barcelona, Spain.
700    1_
$a Lakatos, Péter $u Semmelweis University Medical School, Budapest, Hungary.
700    1_
$a Fahrleitner-Pammer, Astrid $u Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria.
700    1_
$a Lespessailles, Eric $u University Orléans, Orléans, France.
700    1_
$a Minisola, Salvatore $u Policlinico Umberto I, Rome, Italy.
700    1_
$a Body, Jean Jacques $u CHU Brugmann, ULB, Brussels, Belgium.
700    1_
$a Geusens, Piet $u Maastricht University Medical Center, Maastricht, Netherlands.
700    1_
$a Möricke, Rüdiger $u Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany.
700    1_
$a López-Romero, Pedro $u Lilly Research Center, Madrid, Spain.
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 391, č. 10117 (2018), s. 230-240
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29129436 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20200121144219 $b ABA008
999    __
$a ok $b bmc $g 1365024 $s 1039221
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 391 $c 10117 $d 230-240 $e 20171109 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace